Compare Newmont Corporation (NEM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Sana Biotechnology Inc — how do they compare? Newmont Corporation trades at $117.8 (market cap $121.75B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Newmont Corporation is far larger — about 145.5× Sana Biotechnology Inc's market cap, and Newmont Corporation pays a 0.9% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 58 Days and Sana Biotechnology Inc for 23 Days on average.
| NEM | SANA | |
|---|---|---|
Market Cap | $121.75B | $836.71M |
Volume | 5,421,125 | 4,507,444 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $5.92 |
52-Week Low | $78.63 | $2.68 |
Typical Hold Time | 58 Days | 23 Days |
Enterprise Value | $118.34B | $749.96M |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $117.84, up 3.79% over the past 24 hours, with a bearish technical signal but strong fundamental performance. The company reported record free cash flow of $5.3 billion in H1 2026 and has consistently beaten earnings estimates in recent quarters. Revenue grew to $22.67 billion in 2025, with net income reaching $7.09 billion, reflecting a robust profit margin of 31.25%.
The outlook remains positive due to strong cash flow generation and operational improvements, though near-term technical weakness and gold price volatility present risks. Analyst consensus is strongly bullish with a $136.83 price target, indicating potential upside. Key risks include dependence on gold prices and execution of growth projects.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
